Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, Operations | February 28, 2022 | March 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,944 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 2,444 · Balance 54,028 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 1,084 · Balance 52,944 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Exercise / conversion · Disposed 2,444 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004158 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 9,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003565 · doc4.xml · derivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,824 Underlying: Common Stock · 9,824 shares Expires 2021-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · balance_after: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · derivative · entry 9 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,044 | $42.62 | $44,495.28 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 6 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,867 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 5 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · derivative · entry 8 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 Underlying: Common Stock · 2,897 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,314 | $42.62 | $56,002.68 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,611 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · derivative · entry 7 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,178 Underlying: Common Stock · 2,726 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,237 | $42.62 | $52,720.94 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,028 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 33,185 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,185 Underlying: Common Stock · 33,185 shares Expires 2030-02-18 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 8,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,894 Underlying: Common Stock · 8,894 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 23,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,719 Underlying: Common Stock · 23,719 shares Expires 2022-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in one installment on February 18, 2022, the second anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in one installment on February 18, 2022, the second anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · derivative · entry 5 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,306 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,257 | $42.31 | $53,183.67 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,539 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,520 | $42.31 | $318,171.20 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,028 Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 20,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,548 F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 11,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000295 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,926 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,656 | $45.22 | $165,324.32 |
DisclosureSEC source: 0001225208-20-000295 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,387 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000295 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 55,320 | $36.83 | $2,037,297.30 |
DisclosureSEC source: 0001225208-19-007571 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,117 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.575 to $37.14, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 35,906 | $39.72 | $1,426,186.32 |
DisclosureSEC source: 0001225208-19-005111 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,437 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 19,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004585 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,227 Underlying: Common Stock · 19,226 shares Expires 2020-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,546 | $40.75 | $348,249.50 |
DisclosureSEC source: 0001225208-19-004585 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,343 Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 19,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004585 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004346 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,332 Underlying: Common Stock · 2,444 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,087 | $40.12 | $43,610.44 |
DisclosureSEC source: 0001225208-19-004346 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,663 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004346 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · derivative · entry 6 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,299 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,022 | $40.52 | $41,411.44 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · nonDerivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,306 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · nonDerivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · derivative · entry 5 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,794 Underlying: Common Stock · 2,897 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,288 | $40.52 | $52,189.76 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,029 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003726 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 35,310 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003565 · doc4.xml · derivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,310 Underlying: Common Stock · 35,310 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 10,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003565 · doc4.xml · derivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,904 Underlying: Common Stock · 10,904 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 16,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003440 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,318 Underlying: Common Stock · 16,318 shares Expires 2020-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 11,738 | $40.11 | $470,811.18 |
DisclosureSEC source: 0001225208-19-003440 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,420 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 28,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003440 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,158 F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002983 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,074 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 816 | $40.01 | $32,648.16 |
DisclosureSEC source: 0001225208-19-002983 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,190 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002983 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 16,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000437 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,540 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,054 | $35.34 | $178,608.36 |
DisclosureSEC source: 0001225208-19-000437 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,238 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000437 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 19,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005417 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,453 Underlying: Common Stock · 19,226 shares Expires 2020-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,100 | $26.77 | $190,067.00 |
DisclosureSEC source: 0001225208-18-005417 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,752 Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 19,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005417 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.